(March 31, 2014) US Licensing LIVE Rabies Based EBOLA Vaccine, Preps Pandemic Quarantine Stations & Injury Fund
Just in time for the most recent outbreak of Ebola in Africa, which potentially has already spread into North America via Canada, the National Institute for Health is licensing a Rabies-based Ebola vaccine produced by Exxell Bio.
"trivalent filovirus vaccine based on killed rabies virus virions for use in humans to confer protection from all medically relevant filoviruses and RABV. Two additional vectors containing EBOV Sudan GP or MARV GP are planned to be constructed in addition to the previously developed EBOV Zaire GP containing vaccine. Live attenuated vaccines have been developed for use in at risk nonhuman primate populations in Africa and inactivated vaccines have been developed for use in humans."
Basically, what they have done here is taken the Rabies virus and altered its exterior coating to contain Ebola proteins. So if all works as planned, the person vaccinated is protected from Rabies and Ebola.